Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.76
  • Today's Change0.03 / 1.10%
  • Shares traded2.54m
  • 1 Year change-47.92%
  • Beta2.1924
Data delayed at least 15 minutes, as of Jul 18 2025 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Editas Medicine, Inc. is a genome-editing company developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology that includes CRISPR/Cas9, CRISPR/Cas12a, engineered forms and foundational intellectual property for both CRISPR systems. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide RNA molecule designed to recognize a particular DNA sequence. It is engaged in discovering, developing, manufacturing, and commercializing durable, precision in vivo gene-editing medicines for a broad class of diseases. Vivo medicines include vivo editing of hematopoietic stem cells (HSCs), liver cells and other tissues. Vivo gene editing in HSCs supports the advancement of research programs to treat non-malignant hematological diseases.

  • Revenue in USD (TTM)35.84m
  • Net income in USD-251.23m
  • Incorporated2013
  • Employees246.00
  • Location
    Editas Medicine Inc11 Hurley StCAMBRIDGE 02141-2110United StatesUSA
  • Phone+1 (617) 401-9000
  • Fax+1 (302) 655-5049
  • Websitehttps://www.editasmedicine.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
AC Immune SA35.18m-64.75m207.85m133.00--1.76--5.91-0.6484-0.64840.35111.170.1496--47.48264,513.20-27.53-27.41-39.31-30.60-----184.05-505.58---129.200.0518--84.51-24.386.12---21.11--
Larimar Therapeutics Inc0.00-95.23m212.57m65.00--1.47-----1.49-1.490.002.250.00----0.00-45.52-45.05-49.68-50.22------------0.00-------118.15---7.58--
CARGO Therapeutics Inc0.00-216.19m213.51m167.00--0.7494-----4.62-4.620.006.130.00----0.00-55.12---60.88--------------0.00-------70.66------
Tvardi Therapeutics Inc7.57m-45.08m224.47m10.00------29.65-29.62-29.624.97-5.300.11730.005.14757,100.00-69.86-36.79-79.96-41.4566.24---595.39-155.6031.73-------65.96-18.5340.20--125.35--
Eledon Pharmaceuticals Inc0.00-19.05m224.56m31.00--1.96-----0.21-0.210.001.910.00----0.00-15.73-46.29-16.66-48.06------------0.00------68.95------
Lineage Cell Therapeutics Inc9.56m-16.21m226.07m70.00--2.86--23.66-0.0785-0.07850.04530.34610.0868--65.91136,528.60-14.68-20.81-16.75-24.5497.1590.99-169.16-331.61----0.0014--6.1922.0013.39--5.13--
Design Therapeutics Inc0.00-56.20m228.21m56.00--1.00-----0.9918-0.99180.004.010.00----0.00-21.77-18.88-22.44-19.44-------98,925.22----0.00------25.84------
Editas Medicine Inc35.84m-251.23m228.54m246.00--3.66--6.38-3.04-3.040.43380.74570.1018--94.93145,674.80-71.37-34.19-89.03-38.43-----701.06-373.02----0.4665---58.649.50-54.74--7.43--
Tevogen Bio Holdings Inc0.00-31.90m228.71m18.00---------0.2274-0.22740.00-0.0420.00----0.00-950.95-----------------651.35--------83.01------
Ventyx Biosciences Inc0.00-123.99m232.70m81.00--1.00-----1.75-1.750.003.260.00----0.00-42.35-50.81-44.39-53.75------------0.00------29.97------
Codexis Inc49.82m-74.46m238.59m188.00--4.81--4.79-0.9885-0.98850.65080.59910.35786.713.86264,973.40-53.48-21.95-65.18-26.2071.5676.67-149.47-49.883.64--0.3703---15.39-2.8214.38--2.91--
OmniAB Inc26.74m-61.27m239.78m114.00--0.8752--8.97-0.5912-0.59120.25822.240.0812--5.08234,596.50-18.60---19.46-------229.11-101.09----0.00---22.757.58-22.55--49.04--
Entrada Therapeutics Inc172.22m24.78m242.14m183.007.890.58028.471.410.80830.80834.2911.000.3454--4.33941,092.904.97-8.446.16-10.02----14.39-33.36----0.00--63.38--1,081.69--38.04--
Third Harmonic Bio Inc0.00-53.45m245.95m31.00--0.8987-----1.24-1.240.006.060.00----0.00-19.42---19.75--------------0.00-------47.51------
Data as of Jul 18 2025. Currency figures normalised to Editas Medicine Inc's reporting currency: US Dollar USD

Institutional shareholders

32.51%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Mar 20257.40m8.97%
BlackRock Fund Advisorsas of 31 Mar 20256.08m7.37%
Morgan Stanley & Co. LLCas of 31 Mar 20252.55m3.09%
Geode Capital Management LLCas of 31 Mar 20251.94m2.36%
SSgA Funds Management, Inc.as of 31 Mar 20251.85m2.24%
UBS Asset Management Switzerland AGas of 31 Mar 20251.60m1.94%
Bank of America, NA (Private Banking)as of 31 Mar 20251.50m1.82%
Dimensional Fund Advisors LPas of 31 Mar 20251.45m1.75%
Two Sigma Investments LPas of 31 Mar 20251.25m1.51%
Two Sigma Advisers LPas of 31 Mar 20251.22m1.47%
More ▼
Data from 31 Mar 2025 - 31 Mar 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.